11

Simcere Pharmaceutical GroupSimcere Pharmaceutical GroupCorporate PresentationMay 2008

22

Disclaimer

The information contained in this presentation does not constitute or form part of any offer for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. Any public offering of the securities to be made in the United States will be made solely by means of the prospectus in the registration statement. The prospectus contains detailed information about the Company and its management as well as the financial statements of the Company. Any decision to purchase securities in the offering for sale in the United States or anywhere else should be made solely on the basis of the information contained in the prospectus. This presentation does not contain all relevant information relating to the Company or its securities, particularly with respect to the risks and special considerations involved with an investment in the securities of the Company, and is qualified in its entirety by reference to the detailed information appearing in the prospectus.This presentation contains forward-looking statements, including statements about the Company’s business outlook, our strategy and market opportunity, and statements about the Company’s historical results that may suggest trends for its business. These statements are individually and collectively forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are made only as of the date of this presentation and the Company undertakes no obligation to update or revise. These statements are based on estimates and information available to the Company at the time of this presentation and are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Therefore, prospective investors are cautioned that actual results may differ materially from those set forth in any forward-looking statements herein. The information contained in these slides has not been independently verified. No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of any information or opinion contained herein. The information contained in these slides should be considered in the context of the circumstances prevailing at the time and has not been, and will not be, updated to reflect material developments which may occur after the date of the presentation. None of the Company, any underwriter of securities of the Company, or any of their respective directors, officers, employees, agents or advisers shall be in any way responsible for the contents hereof, or shall be liable for any loss arising from use of the information contained in this presentation or otherwise arising in connection therewith.Before you invest, you should read the prospectus in the registration statement the Company filed with SEC and other documents the Company has filed with the SEC for more complete information about the Company and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, you may request the prospectus by sending us a request via our website at www.simcere.com.

33

Highlights

III Unique Play on Fast-Growing China Healthcare Market

IIIIIICore Competencies and Differentiated Growth Strategy Ensure Industry Leading Position

IIIIIIIII Track Record of Outstanding Financial Performance and Operational Execution

44

Simcere at a Glance

Simcere is a leading manufacturer and supplier of first-to-market branded generic and innovative pharmaceuticals in the rapidly growing China market.

IPO date: April 2007. IPO price: USD14.5. IPO proceeds (net): US$162 million

2007: Revenue RMB1,389.3 million (US$190.5 million); Net Income RMB301.3 million (US$41.3 million)

2008: Revenue guidance RMB2.0 billion – RMB2.1 billion; Net income RMB390 million – RMB400 million

Strategic developments in 2007-2008:Completed acquisition of 10% equity interest in Shandong Simcere Medgenn Bio- Pharmaceutical Company Limited, an existing subsidiary, for RMB27.1 million

Completed acquisition of 51% ownership in Boda Pharmaceutical to capture 100% of the fast-growing injectableedaravone market

Acquired 85% equity interest in Nanjing Tung Chit Pharmaceutical and obtained the market leading chemotherapeutic drug Jiebaishu

Acquired 70% equity interest in Zhong Ren Pharmaceutical, gaining rights to SinoFuan, the only sustained release anti-tumor implant approved by the State Food and Drug Administration (SFDA)

Received SFDA approval to manufacture and sell first-to-market generic Biapenem injection Anxin

55

Fast-Growing Market DemandFastFast--Growing Market DemandGrowing Market Demand

Simcere Offers Unique Play on Fast-Growing Chinese Healthcare Market

Source: The Freedonia Group

Key DriversKey Key DriversDrivers

111 GDP & Disposable Income Growth

222 Aging Population & Increasing Lifestyle Related Diseases

333

Government Support & Cost Efficiency444

Improving Health Insurance Program and Coverage

555Fragmented Industry Calling for Consolidation0

100

200

300

400

500

600

700

2000

2001

2002

2003

2004

2005

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

USD BillionAcceleration phase:

2007-2010 > 20%

66

Core Competencies and Differentiated Growth Strategy Ensure Industry Leading Position

The Only Large NYSE Listed China Drug Maker Play Into The Fast Growing Pharmaceutical Market

Focused Strategy: First-to-Market and Innovative Drugs

Leader in Marketing Network and Deep Channel Penetration

Increasing In-House R&D

Proven Acquisition and Integration Capabilities

77

Branded GenericsMarketing

&Distribution

Manufacturing

Innovative Drug

1990’s Early 2000’s

FTM Generics

Branded Generics

Marketing &Distribution

Marketing &Distribution

Branded Generics

R&D

Manufacturing

Marketing &Distribution

Branded Generics

Mid 2000’s Now and On

R&D

ManufacturingFTM Generics

Growing from a distributor to a distribution, production and R&D integrated companyShifting from generic to first-to-market and new drug focused product portfolio

Differentiated Business Model Provides Ongoing Stability and Growth

Differentiated Growth Strategy: First-to-Market and Innovative Drugs

Growing from a distributor to a distribution, production and R&DGrowing from a distributor to a distribution, production and R&D integrated companyintegrated companyShifting from generic to firstShifting from generic to first--toto--market and new drug focused product portfoliomarket and new drug focused product portfolio

Differentiated Business Model Provides Ongoing Stability and GroDifferentiated Business Model Provides Ongoing Stability and Growthwth

88

Proven Marketing Power & Deep Channel Penetration

Over 1,500 in-house and outsourced sales professionals Specialized in neurology, oncology and cerebrovascularpromotionStrong commercial channel operation experience

Over 2,000 hospitalsOver 2,000 hospitalsOver 2,000 hospitals Over 70,000 retail pharmacies

Over 70,000 retail Over 70,000 retail pharmaciespharmacies

Nationwide Distribution Network – 1,500 distributors

Proven Ability To- Optimize Positioning and Pricing - Execute Large Scale Market Promotions- Build Up Brand and Loyalty - Introduce New Products

Proven Ability ToProven Ability To-- Optimize Positioning and PricingOptimize Positioning and Pricing -- Execute Large Scale Market PromotionsExecute Large Scale Market Promotions-- Build Up Brand and Loyalty Build Up Brand and Loyalty -- Introduce New ProductsIntroduce New Products

Brands & Brand LoyaltyBrands & Brand LoyaltyBrands & Brand Loyalty

99

Amoxicillin with clavulanate potassium antibiotic granules, tablets and injections

Amoxicillin capsules, dispersible antibiotic tablets, granules and injections

Diclofenac sodium capsules for anti-inflammation

Smectite powder for anti-diarrhea

Product Portfolio with Focus on Oncology and Cerebrovascular Diseases

Products in OtherProducts in OtherTherapeuticTherapeutic

AreasAreas

OncologyOncology

CerebrovascularDiseases

An innovative anti-cancer product, recombinant human endostatin injection

Edaravone injections, free-radical scavenger for stroke management

Nedaplatin a platinum based chemotherapeutic drug

5-Fu sustained release anti-tumor implant

EnduEndu

Bicun & Bicun & YidashengYidasheng

JiebaishuJiebaishu

SinofuanSinofuan

ZailinZailin

AnqiAnqi

YingtaiqingYingtaiqing

BiqiBiqi

1010

Building Oncology Product Line– Innovative Drug Endu

Endu revenue expected to grow 40-50% in 2008

Phase IV interim report of over 600 patients expected to be published in June 2008

3.4 6.614.6

29.5

58.8

0

20

40

60

80

100

1995 2000 2005 2010 2015

(RM

B i

n bi

llion

)

Exciting Performance of Endu Since LaunchExcitingExciting Performance Performance ofof EnduEndu SinceSince LaunchLaunch Demand for Antineoplastic AgentsDemand for Demand for AntineoplasticAntineoplastic AgentsAgents

34.8

216.1

40% to 50%growth

0.0

60.0

120.0

180.0

240.0

300.0

360.0

2006H2 FY2007 2008E

(RM

B i

n m

m)

Quick adoption by approximately 800 hospitals in China

Over 10,000 patients already treated by Endu, all paid out of own pockets

1111

Fast-Growing Cerebrovascular & Cardiovascular Product Line – Bicun & Yidasheng

Source： IMS Health

Patients Treated with Edaravone

8.8%

According to statistical research, China has 1.8 million cases of stroke being treated each year

Full year 2007 sales RMB443.4 million; Q1 sales RMB 152.0 million, an increase of 89% year on year

Drug of choice for treating stroke

Therapeutic use expanding from neurology to other hospital departments

Boda acquisition enabled Simcere to stabilize price of both edaravone injections in the market

Integrated marketing capabilities of the two brands, expect over 80% total sales growth in edaravone market for 2008

Raised barrier of entry for future competitors; price remains stable post-monitoring period

Sales of Bicun & YidashengSales of Sales of BicunBicun & & YidashengYidasheng

Edaravone Market ShareEdaravoneEdaravone Market ShareMarket Share

230.9

443.5

80% growth

0.060.0

120.0180.0240.0300.0360.0420.0480.0540.0600.0660.0720.0780.0840.0

2006 2007 2008 (E)

(RM

B i

n m

m)

1212

Key Product Candidate

Key Product Key Product CandidateCandidate

Therapeutic Areas

Therapeutic Therapeutic AreasAreas

Expected Time of

Introduction

Expected Expected Time of Time of

IntroductionIntroduction

StatusStatusStatus

SFDA Approval May 2008

Pre-clinicalPrePre--

clinicalclinicalPhase

IPhasePhase

IIPhase

IIPhasePhase

IIIIPhase

IIIPhasePhase

IIIIIINew Drug ApplicationNew Drug New Drug ApplicationApplication

2008

2009

Drug Optimization

Drug Drug OptimizationOptimization

Lead Discovery

Lead Lead DiscoveryDiscovery INDINDIND

2009

2009

2009(IND)

2009(IND)

2009(IND)

2009(IND)

2009(IND)

2009(IND)

Serious Infection Biapenem injection

Anti-inflammatory Iguratimod tablets

Oncology Palonosetron injection

Oncology Endu combined with TC Therapy

Oncology Endu combined with NP Therapyv

Oncology (Docetaxel Liposome for Injection)

Oncology SIM6802(protein tyrosine kinaseinhibitor)

Oncology SIM060301 (protein tyrosine kinase inhibitor)

Oncology SIM0710 (PEG-Endostarfor Injection)

Oncology SIM0702(Endostar Depot for Injection)

CerebrovascularDiseases

SIM071201

Expanding Pipeline to Secure Sustainable Growth

1313

19.9 16.334.3

100.0

68.3

020406080

100120

2004 2005 2006 2007 2008(E)

(RM

B M

)

R&D Expenses

R&D InvestmentR&D InvestmentR&D InvestmentR&D ApproachR&DR&D ApproachApproach

R&D strategies:

Source product candidates in China and overseas

Carry out extensive development on existing key products

Collaborate with domestic and international pharmaceutical companies and institutions

Competitive advantages:

Low R&D and clinical trial cost advantage

Leading R&D facilities in China and well trained research staff (more than 20 staff with PhDs)

A leading new drug developer in China, demonstrated by successfully developed Bicun

Increasing R&D Investment

Intellectual PropertyIntellectual PropertyIntellectual Property

Authorized Patents : 37

Pending Patents (China): 46

Trademarks: 269

National Brand Name Trademarks: 2

1414

Successful Acquisition & Integration Strategy- Leveraging proven consolidation capabilities to capitalize on fragmented market

Simcere Dongyuan Pharmaceutical Co., Ltd.

Boda Pharmaceutical Co., Ltd.

Hainan Simcere Pharmaceutical Co., Ltd.

Simcere Tung Chit Pharmaceutical Co., Ltd.

Wuhu Zhong Ren Pharmaceutical Co., Ltd

2001

2003

2006 Shandong Simcere MedgennBiopharmaceutical Co., Ltd.

2007

2007

2008

M&A Targets

Quality products with blockbuster potential First-to-market new drugs and branded genericsProducts that will leverage existing resources

Simcere is capable of financing and integrating acquisition target

Strong working capital reserve to support potential transactionsStrong cash balance of RMB950 millionMore strategic acquisitions to come in 2008

1515

301

172

103

46

395

0

50

100

150

200

250

300

350

400

2004 2005 2006 2007 2008(E)

(RM

B M

)

Net Income

Outstanding Financial Performance – Five consecutive years of robust revenue and net income growth

RevenueRevenueRevenue Net IncomeNet IncomeNet Income

564

737

951

1389

2050

0

500

1,000

1,500

2,000

2004 2005 2006 2007 2008(E)

(RM

B M

)

Revenue

2008(E)* being the median of the range of estimated revenue and 2008(E)* being the median of the range of estimated revenue and net income guidance provided.net income guidance provided.

CAGR=71%

CAGR=38%

1616

Growing FTM and Innovative Drug Revenue – Driving Higher Gross Margin

FY2007FY2007FY2007

Innovative 4%

FTM Generic

24%

Branded Generics

72%FTM Generic 33%

Innovative 16%

Branded Generics

51%

FTM Generic

19%

Branded Generics 81%

2008Q12008Q12008Q1

82.3%79.9%

76.8%

72.7%

70%

75%

80%

85%

2004 2005 2006 2007

Gross Margin

FY2005FY2005FY2005 FY2006FY2006FY2006

Innovative 16%

FTM Generic 39%

Branded Generics

45%

1717

Investment Highlights

Unique Opportunity For Exposure To Fast-Growing Chinese Healthcare Market

The largest Chinese drug maker listed on the NYSE

Strong upside potential

Extensive marketing network and proven sales capabilitiesKey to success in China healthcare market

Expanding product pipeline and increasingly diversified portfolio

Successful consolidator in fragmented market